Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-022-14877-5 http://scihub22266oqcxt.onion/10.1038/s41598-022-14877-5 35760825!9237110!35760825     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2022 ; 12 (1): 10852 Nephropedia Template TP {{tp|p=35760825|t=2022. A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa |pdf=|usr=}}{{35760825}} gab.com Text A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=35760825 #FOAvip The recent outbreak of COVID-19 has increased hospital admissions, which could elevate the risk of nosocomial infections, such as A. baumannii and P. aeruginosa infections. Although effective vaccines have been developed against SARS-CoV-2, no approved treatment option is still available against antimicrobial-resistant strains of A. baumannii and P. aeruginosa. In the current study, an all-in-one antigen was designed based on an innovative, state-of-the-art strategy. In this regard, experimentally validated linear epitopes of spike protein (SARS-CoV-2), OmpA (A. baumannii), and OprF (P. aeruginosa) were selected to be harbored by mature OmpA as a scaffold. The selected epitopes were used to replace the loops and turns of the barrel domain in OmpA; OprF(311-341) replaced the most similar sequence within the OmpA, and three validated epitopes of OmpA were retained intact. The obtained antigen encompasses five antigenic peptides of spike protein, which are involved in SARS-CoV-2 pathogenicity. One of these epitopes, viz. QTQTNSPRRARSV could trigger antibodies preventing super-antigenic characteristics of spike and alleviating probable autoimmune responses. The designed antigen could raise antibodies neutralizing emerging variants of SARS-CoV-2 since at least two epitopes are consensus. In conclusion, the designed antigen is expected to raise protective antibodies against SARS-CoV-2, A. baumannii, and P. aeruginosa. Twit Text FOAVip A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=35760825 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35760825 #FOAvip English Wikipedia <ref>{{Cite pmid|35760825}}</ref> A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa #MMPMID35760825 Rahbar MR; Mubarak SMH; Hessami A; Khalesi B; Pourzardosht N; Khalili S; Zanoos KA; Jahangiri A Sci Rep 2022[Jun]; 12 (1): 10852 PMID35760825show ga The recent outbreak of COVID-19 has increased hospital admissions, which could elevate the risk of nosocomial infections, such as A. baumannii and P. aeruginosa infections. Although effective vaccines have been developed against SARS-CoV-2, no approved treatment option is still available against antimicrobial-resistant strains of A. baumannii and P. aeruginosa. In the current study, an all-in-one antigen was designed based on an innovative, state-of-the-art strategy. In this regard, experimentally validated linear epitopes of spike protein (SARS-CoV-2), OmpA (A. baumannii), and OprF (P. aeruginosa) were selected to be harbored by mature OmpA as a scaffold. The selected epitopes were used to replace the loops and turns of the barrel domain in OmpA; OprF(311-341) replaced the most similar sequence within the OmpA, and three validated epitopes of OmpA were retained intact. The obtained antigen encompasses five antigenic peptides of spike protein, which are involved in SARS-CoV-2 pathogenicity. One of these epitopes, viz. QTQTNSPRRARSV could trigger antibodies preventing super-antigenic characteristics of spike and alleviating probable autoimmune responses. The designed antigen could raise antibodies neutralizing emerging variants of SARS-CoV-2 since at least two epitopes are consensus. In conclusion, the designed antigen is expected to raise protective antibodies against SARS-CoV-2, A. baumannii, and P. aeruginosa. |*Acinetobacter Infections[MESH] |*Acinetobacter baumannii/metabolism[MESH] |*COVID-19[MESH] |Epitopes[MESH] |Humans[MESH] |Pseudomonas aeruginosa[MESH] |SARS-CoV-2[MESH]A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseu(epmc).pdf DeepDyve Pubget Overpricing